146 related articles for article (PubMed ID: 29449680)
21. Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
Udager AM; Liu TY; Skala SL; Magers MJ; McDaniel AS; Spratt DE; Feng FY; Siddiqui J; Cao X; Fields KL; Morgan TM; Palapattu GS; Weizer AZ; Chinnaiyan AM; Alva A; Montgomery JS; Tomlins SA; Jiang H; Mehra R
Ann Oncol; 2016 Sep; 27(9):1706-12. PubMed ID: 27217541
[TBL] [Abstract][Full Text] [Related]
22. Analysis of PD-L1 expression and T cell infiltration in different molecular subgroups of diffuse midline gliomas.
Jha P; Manjunath N; Singh J; Mani K; Garg A; Kaur K; Sharma MC; Raheja A; Suri A; Sarkar C; Suri V
Neuropathology; 2019 Dec; 39(6):413-424. PubMed ID: 31625205
[TBL] [Abstract][Full Text] [Related]
23. Inflammatory myofibroblastic tumor of the uterus: a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum.
Bennett JA; Nardi V; Rouzbahman M; Morales-Oyarvide V; Nielsen GP; Oliva E
Mod Pathol; 2017 Oct; 30(10):1489-1503. PubMed ID: 28664932
[TBL] [Abstract][Full Text] [Related]
24. Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes.
Shurell E; Singh AS; Crompton JG; Jensen S; Li Y; Dry S; Nelson S; Chmielowski B; Bernthal N; Federman N; Tumeh P; Eilber FC
Oncotarget; 2016 Sep; 7(39):64300-64308. PubMed ID: 27588404
[TBL] [Abstract][Full Text] [Related]
25. PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.
Bertolini G; Bergamaschi L; Ferrari A; Renne SL; Collini P; Gardelli C; Barisella M; Centonze G; Chiaravalli S; Paolino C; Milione M; Massimino M; Casanova M; Gasparini P
BMC Cancer; 2018 Jun; 18(1):652. PubMed ID: 29898687
[TBL] [Abstract][Full Text] [Related]
26. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma.
Lee LH; Cavalcanti MS; Segal NH; Hechtman JF; Weiser MR; Smith JJ; Garcia-Aguilar J; Sadot E; Ntiamoah P; Markowitz AJ; Shike M; Stadler ZK; Vakiani E; Klimstra DS; Shia J
Mod Pathol; 2016 Nov; 29(11):1433-1442. PubMed ID: 27443512
[TBL] [Abstract][Full Text] [Related]
27. PD-L1 Expression and CD8
Wang Y; Zhu C; Song W; Li J; Zhao G; Cao H
J Immunol Res; 2018; 2018():4180517. PubMed ID: 30003113
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory myofibroblastic tumor of the uterus: a clinicopathologic study of 6 cases emphasizing distinction from aggressive mesenchymal tumors.
Rabban JT; Zaloudek CJ; Shekitka KM; Tavassoli FA
Am J Surg Pathol; 2005 Oct; 29(10):1348-55. PubMed ID: 16160478
[TBL] [Abstract][Full Text] [Related]
29. Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability.
Ma C; Patel K; Singhi AD; Ren B; Zhu B; Shaikh F; Sun W
Am J Surg Pathol; 2016 Nov; 40(11):1496-1506. PubMed ID: 27465786
[TBL] [Abstract][Full Text] [Related]
30. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
31. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
[TBL] [Abstract][Full Text] [Related]
32. PD-L1 expression in angiomatoid fibrous histiocytoma.
Byers J; Yin H; Rytting H; Logan S; He M; Yu Z; Wang D; Warren M; Mangray S; Dehner LP; Zhou S
Sci Rep; 2021 Jan; 11(1):2183. PubMed ID: 33500467
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological implications of the expression of vascular endothelial growth factor and programmed death ligand 1 in clear-cell renal cell carcinoma.
Lee KS; Yun S; Lee K; Moon S; Choe G
Hum Pathol; 2020 May; 99():88-97. PubMed ID: 32246989
[TBL] [Abstract][Full Text] [Related]
35. Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma.
Koelzer VH; Gisler A; Hanhart JC; Griss J; Wagner SN; Willi N; Cathomas G; Sachs M; Kempf W; Thommen DS; Mertz KD
Histopathology; 2018 Sep; 73(3):397-406. PubMed ID: 29660160
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the Pleura.
Tapias LF; Mino-Kenudson M; Choy E; Kem M; Muniappan A; Gaissert HA; Wright CD; Ott HC; Mathisen DJ; Lanuti M
Ann Thorac Surg; 2021 Dec; 112(6):1862-1869. PubMed ID: 33347847
[TBL] [Abstract][Full Text] [Related]
37. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors.
Bedekovics J; Beke L; Mokanszki A; Szilagyi S; Mehes G
Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):1-9. PubMed ID: 30499814
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
Inaguma S; Wang Z; Lasota J; Sarlomo-Rikala M; McCue PA; Ikeda H; Miettinen M
Am J Surg Pathol; 2016 Aug; 40(8):1133-42. PubMed ID: 27158757
[TBL] [Abstract][Full Text] [Related]
40. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.
Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL
Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
